News Release

Printer Friendly Version View printer-friendly version << Back
July 10, 2001 at 12:00 AM EDT

Quidel Receives Significant Patent Protection on LTF Technology

SAN DIEGO, July 10 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced receipt of notification that another of the Company's U.S. patent applications for its Reporter Enzyme Release Technology was issued on June 26, 2001, as U.S. Patent No. 6,251,621. This broad patent covers the use of the proprietary Quidel LTF (Layered Thin Film) technology to detect with great sensitivity a group of enzymes called hydrolases and their inhibitors.

Hydrolases are enzymes produced by infectious agents including bacteria, viruses, protozoa and yeast that can serve as important virulence factors for these pathogens. Hydrolases can also be present in bodily fluids as a result of diseases such as cancer and hepatitis.

"Sensitive detection of disease-associated hydrolases can assist rapid diagnosis of disease and facilitate prompt therapeutic intervention," commented S. Wayne Kay, President and Chief Operating Officer. "Quidel's LTF technology platform permits new methods for simple, rapid, cost-effective and sensitive detection of these disease markers in POC settings."

The patent also covers systems for detecting hydrolase inhibitors. "This is important because many therapeutic agents including antibiotics, antiviral agents and many newer therapeutic drugs function by selectively inhibiting hydrolases," added Kay. "Hence, large-scale screening for hydrolase inhibitors and selection of appropriate drug candidates can depend on simple and sensitive hydrolase detection methods. The patented Quidel detection systems, therefore, have broad potential application to worldwide drug discovery and to the development of new methods for therapeutic monitoring."

About Quidel Corporation
Quidel Corporation discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs, and increase patient satisfaction. For more information, please visit Quidel's Web site at http://www.quidel.com.

This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes (both domestically and internationally) in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

Bruce Voss, bvoss@lhai.com,
or Martin Halsall, mhalsall@lhai.com,
both of Lippert/Heilshorn & Associates, 310-691-7100, for Quidel Corporation;
or Sharon Platt, Investor Relations Associate, 858-552-7955,
or S. Wayne Kay, President & COO, 858-646-8063,
both of Quidel Corporation